Celgene Corporation patented THALOMID (thalidomide) and REVLIMID (lenalidomide – a thalidomide derivative) as well as other pharmaceuticals. If you think these drugs are being introduced slowly and cautiously, just take a look at the revenue for 2008 in this report. Also of particular interest, which speaks to the aggressive marketing, is the distribution of REVLIMID from about 30 countries to over 65. One of the many 2009 Corporate objectives is “Maximize the Clinical, Regulatory, and Commercial Potential of REVLIMID®, VIDAZA®, Global THALOMID®/Thalidomide and Pomalidomide in Nearly 75 Countries”. Be sure to scroll down to see their “Recent Developments and Highlights” and “2009 Selected Corporate Objectives”.
It is obvious that thalidomide is not only back, but is picking up speed around the world.
Celgene Reports Record Fourth Quarter and Full Year 2008 Product Sales and Operating Profits
Thursday, February 5, 2009
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment